Control Bionics Limited (ASX: CBL) - Share Price
Current share price for CBL : $0.059 0.001 (1.67%)+
Control Bionics Limited (CBL) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a Company that is engaged in development, commercialisation and sale of assistive communications technology systems within the disability sector.
CBL General Information +
| ASX Code | CBL |
| Website | N/A |
| Industry/Sector | Health Care Equipment |
| Market Cap ($M) | 32 |
| CBL Share Price | $0.059 |
| Day High | $0.061 |
| Day Low | $0.059 |
| Last Close | $0.060 |
| CBL Share Price Movement | $0.00 ( 1.67% ) |
Prices as at 16:35, 14 Aug 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Control Bionics Limited (CBL) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Result | 1.35¢ | 0% | 8 Sep 2017 | 21 Sep 2017 | - | - | - |
| HFResult | 1.83¢ | 0% | 13 Mar 2017 | 31 Mar 2017 | - | - | - |
| Result | 2.83¢ | 0% | 27 Oct 2016 | 4 Nov 2016 | - | - | - |
See all dividends from Control Bionics Limited (CBL) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Control Bionics Limited (CBL) price-sensitive announcements
CBL - US FDA Registration and Device Listing for NeuroStrip
Control Bionics Limited has successfully registered and listed its NeuroStrip™ surface EMG
Control Bionics Limited (CBL)
4 Aug 2026 | 8:26 AM
4 Aug 2026 | 8:26 AM
CBL - Commercial momentum builds across both platform pillars
Control Bionics Limited, a non-invasive neurotechnology platform company, announced signif
Control Bionics Limited (CBL)
31 Jul 2026 | 9:10 AM
31 Jul 2026 | 9:10 AM
CBL - Quarterly Activities/Appendix 4C Cash Flow Report
Control Bionics Limited reported a strong quarter ending 30 June 2026, highlighted by the
Control Bionics Limited (CBL)
31 Jul 2026 | 8:31 AM
31 Jul 2026 | 8:31 AM
CBL - Completion of Placement
Control Bionics Limited has announced a capital raising initiative, securing firm commitme
Control Bionics Limited (CBL)
25 Jun 2026 | 10:40 AM
25 Jun 2026 | 10:40 AM
Control Bionics Limited (CBL) Recent ASX Announcements
CBL Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$6.11 | -$2.30 | -37.50% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$5.91 | -$3.60 | -34.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$5.63 | -$5.50 | -12.80% | 0.00 | 0.00 | 0.00% | 0.0% |
CBL Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Control Bionics Limited (CBL) | $34M | -0.3747 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Cochlear Limited (COH) | $8,612M | 0.0171 | -0.1894 | 0.0615 | 22.0042 | 27.1460 | 25.5724 | 3.27% | 2.63% | 2.73% |
| Fisher & Paykel Healthcare Corporation Limited (FPH) | $20,720M | 0.1388 | 0.1488 | 0.1884 | 53.3495 | 46.4394 | 39.0784 | 1.23% | 1.33% | 1.50% |
| ResMed Inc. (RMD) | $18,598M | 0.3087 | 9.7744 | 0.0800 | 216.2999 | 20.0753 | 18.5886 | 1.06% | 1.14% | 1.24% |
CBL Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Jeremy Steele | Chief Executive Officer, Executive Director | 19 Jan 2023 |
| Mr Stephen R Rix | Non-Executive Chairman, Non-Executive Director | 1 Dec 2025 |
| Professor Robert Heard | Non-Executive Director | 3 May 2023 |
| Mr Damian Lismore | Non-Executive Director, Interim Chairman | 30 Sep 2020 |
| Professor Nicholas Opie | Non-Executive Director, Strategic advisor | 14 May 2026 |
Control Bionics Limited (CBL) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 12 Aug 2026 | STEELE, Jeremy | Issued | Indirect Shares | 1,000,160 | $0.075 | $75,012.000 |
| 12 Aug 2026 | RIX, Stephen | Issued | Indirect Shares | 2,040,000 | $0.075 | $153,000.000 |
| 12 Aug 2026 | HEARD, Robert | Issued | Indirect Shares | 333,333 | $0.075 | $25,000.000 |
See all changes in directors' interest & trades for Control Bionics Limited (CBL) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
CBL Management
| Name | Position |
|---|---|
| Shannon Boothroyd | Chief Financial Officer |
| Brett Thomas Crowley | Company Secretary |
| Todd Tyler | US Country Manager |
CBL Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Control Bionics Limited (CBL). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 58,495,641 (19.85%) | Phoenix Development Fund Limited |
| 56,292,796 (19.10%) | Nightingale Partners Pty Limited |
| 20,003,433 (10.04%) | Peter Shann Ford |
CBL Calendar of Events
| Date | Event |
|---|---|
| 25 February 2027 | Report (Interim) |
| 11 September 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
